» Articles » PMID: 17512085

Insulin Resistance in Hepatocytes and Sinusoidal Liver Cells: Mechanisms and Consequences

Overview
Journal J Hepatol
Publisher Elsevier
Specialty Gastroenterology
Date 2007 May 22
PMID 17512085
Citations 123
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatic insulin resistance is an important underlying cause of the metabolic syndrome that manifests itself in diseases such as diabetes type II, atherosclerosis or non-alcoholic fatty liver disease (NAFLD). In this paper, we summarize comprehensively the current state of knowledge pertaining to the molecular mechanisms that lead to insulin resistance in hepatocytes and sinusoidal liver cells. In hepatocytes, the insulin resistant state is brought about by at least one, but more likely by a combination, of the following pathological alterations: hyperglycaemia and hyperinsulinaemia, formation of advanced glycation end-products, increased free fatty acids and their metabolites, oxidative stress and altered profiles of adipocytokines. Insulin resistance in hepatocytes distorts directly glucose metabolism, especially the control over glucose output into the circulation and interferes with cell survival and proliferation, while hepatic fatty acid synthesis remains stimulated by compensatory hyperinsulinaemia, resulting in steatosis. Very few studies have addressed insulin resistance in sinusoidal liver cells. These cells are not simply bystanders and passive witnesses of the changes affecting the hepatocytes. They are target cells that will respond to the pathological alterations occurring in the insulin resistant state. They are also effector cells that may exacerbate insulin resistance in hepatocytes by increasing oxidative stress and by secreting cytokines such as TNF and IL-6. Moreover, activation of sinusoidal endothelial cells, Kupffer cells and stellate cells will lead to chemo-attraction of inflammatory cells. Finally, activation of stellate cells will set in motion a fibrogenic response that paves the way to cirrhosis.

Citing Articles

Type 2 Diabetes Mellitus: New Pathogenetic Mechanisms, Treatment and the Most Important Complications.

Mlynarska E, Czarnik W, Dzieza N, Jedraszak W, Majchrowicz G, Prusinowski F Int J Mol Sci. 2025; 26(3).

PMID: 39940862 PMC: 11817707. DOI: 10.3390/ijms26031094.


Experimental cell models of insulin resistance: overview and appraisal.

Yang Y, Wang T, Xie H, Hu P, Li P Front Endocrinol (Lausanne). 2025; 15:1469565.

PMID: 39749015 PMC: 11693592. DOI: 10.3389/fendo.2024.1469565.


Association between Body Mass Index and Serum Uric Acid: mediation analysis involving liver enzymes indicators.

Deng F, Wang Q, Wen X, Xu X, Jia L, He H BMC Public Health. 2024; 24(1):3007.

PMID: 39478457 PMC: 11526625. DOI: 10.1186/s12889-024-20457-1.


Investigating the Mechanisms of 15-PGDH Inhibitor SW033291 in Improving Type 2 Diabetes Mellitus: Insights from Metabolomics and Transcriptomics.

Huang Y, Liang M, Liao Y, Ji Z, Lin W, Pu X Metabolites. 2024; 14(9).

PMID: 39330516 PMC: 11434390. DOI: 10.3390/metabo14090509.


Marine-Derived Phosphoeleganin and Its Semisynthetic Derivative Decrease IL6 Levels and Improve Insulin Signaling in Human Hepatocellular Carcinoma Cells.

Agognon A, Casertano M, Vito A, Orso S, Cabaro S, Mormone F Int J Mol Sci. 2024; 25(11).

PMID: 38892230 PMC: 11173279. DOI: 10.3390/ijms25116039.